Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus

Treatment of systemic lupus erythematosus: new advances in targeted therapy

(2012) Mindy S. Lo et al.   Annals of the New York Academy of Sciences

Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice

(2012) L. P. Kil et al.   BLOOD

The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils

(2012) Fumiko Honda et al.   NATURE IMMUNOLOGY

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

(2011) S. E. M. Herman et al.   BLOOD

Targeting lymphocyte signaling pathways as a therapeutic approach to systemic lupus erythematosus

(2011) Vasileios C. Kyttaris et al.   CURRENT OPINION IN RHEUMATOLOGY

Bruton's Tyrosine Kinase Is Required for TLR-Dependent Heme Oxygenase-1 Gene Activation via Nrf2 in Macrophages

(2011) V. Vijayan et al.   JOURNAL OF IMMUNOLOGY

The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells

(2011) Betty Y Chang et al.   ARTHRITIS RESEARCH & THERAPY

Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia

(2010) K. Fiedler et al.   BLOOD

Tyrosine kinase Btk regulates E-selectin-mediated integrin activation and neutrophil recruitment by controlling phospholipase C (PLC)  2 and PI3K  pathways

(2010) H. Mueller et al.   BLOOD

Separate checkpoints regulate splenic plasma cell accumulation and IgG autoantibody production in Lyn-deficient mice

(2010) Toni Gutierrez et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Constitutive activation of Bruton's tyrosine kinase induces the formation of autoreactive IgM plasma cells

(2010) Rogier Kersseboom et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

B Cell Subsets Contribute to Renal Injury and Renal Protection after Ischemia/Reperfusion

(2010) B. Renner et al.   JOURNAL OF IMMUNOLOGY

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

(2010) L. A. Honigberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

(2009) Joan T. Merrill et al.   ARTHRITIS AND RHEUMATISM

Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain

(2009) Abdalla J. Mohamed et al.   IMMUNOLOGICAL REVIEWS

The Lupus Susceptibility Locus Sle1 Breaches Peripheral B Cell Tolerance at the Antibody-Forming Cell and Germinal Center Checkpoints

(2009) R. Vuyyuru et al.   JOURNAL OF IMMUNOLOGY

Btk regulates localization, in vivo activation, and class switching of anti-DNA B cells

(2008) Kristina E. Halcomb et al.   MOLECULAR IMMUNOLOGY

B cells and tertiary lymphoid organs in renal inflammation

(2007) S. Segerer et al.   KIDNEY INTERNATIONAL